

UPDATE IN PERIOPERATIVE MEDICINE

Noncardiac
elective or semi-
elective surgery



Malathi Srinivasan, MD FACP
Clinical Professor of Medicine

Stanford University School of Medicine
Northern California American College of Physicians
October 2019

Disclosures

- No conflicts of interest
- Liberally used web-based images
- Great material from CCA/ACC



“Now, I can say that I’ve officially seen everything”

Key Updates (4 cases)

- 1 Anticoagulation
- 2 Cardiac Risk Stratification
- 3 Hypertension Meds
- 4 PCI and Stents



Goals of Perioperative Evaluation



Optimize Perioperative Risk

Identify highest risk periop patients

230 Million

Surgeries worldwide/year

3 Million

Post-op deaths worldwide

10 Million

Major Adverse Cardiac Events

4%

Surgical death rate @ 7 days (Based on UK data)

53 Million

US ambulatory procedures

10%

- Patients driving most complications
- Serious complication rate unchanged
- ERAS (enhanced recovery after surgery)

has 33% fewer post-op complications (15K, Kaiser)

Perioperative anticoagulation



Perioperative anticoagulation: DOAC?



Factor Xa inhibitors



Factor IIa inhibitors

COUMADIN® (warfarin sodium)



Vitamin K
antagonist


Peri-procedural
Major Bleeding
Risk

Peri-procedural
Thrombotic Risk



Major Bleeding

- Fatal bleed
- $Hb \geq 2g$ drop or $\geq 2UPRBC$
- Needs surgical correction



Perioperative anticoagulation

88yo woman with afib on Xarelto (no prior strokes) has mild bloody stools. CT shows colonic mass, colonoscopy planned in 1 week. VSS. Periop: What shall we do with her rivaroxaban (Xarelto)?

- a. Continue rivaroxaban through colonoscopy
- b. Stop rivaroxaban 2 days before; bridge with heparin/Imwh
- c. Stop rivaroxaban 2 days before; restart after hemostasis

Perioperative anticoagulation

88yo woman with afib on Xarelto (no prior strokes) has mild bloody stools. CT shows colonic mass, colonoscopy planned in 1 week. VSS. Periop: What shall we do with her rivaroxaban (Xarelto)?

- a. Continue rivaroxaban through colonoscopy
- b. Stop rivaroxaban 2 days before; bridge with heparin/Imwh
- c. **Stop rivaroxaban 2 days before; restart after hemostasis**



JAMA Internal Medicine | Original Investigation

Perioperative Management of Patients With Atrial Fibrillation Receiving a Direct Oral Anticoagulant

James D. Douketis, MD, Alex C. Spyropoulos, MD, Joanne Duncan, BSc, Marc Carrier, MD, MSc, Gregoire Le Gal, MD, Alfonso J. Tafar, MD, Thomas Vanasse, MD, Peter Verhaeghe, MD, Sudheep Shivakumar, MD, Peter L. Gross, MD, MSc, Agnes Y. Y. Lee, MD, MSc, Erik Yoo, MD, Susan Solymoss, MD, Joanne Kozak, MD, Genevieve Le Tremblay, MD, Stephen Kowaluk, MD, Mark Hladstein, MD, Vinay Shah, MD, Elizabeth Mackay, MD, Cynthia Wu, MD, Nathan P. Clark, PharmD, Shannon M. Bates, MDCM, MSc, Frederick A. Spencer, MD, Eleni Anagnostou, MD, PhD, Michael Coppens, MD, PhD, Donald M. Arnold, MD, MSc, Joseph A. Caprini, MD, Na Li, PhD, Karen A. Moffat, MEd, Summer Syed, MD, MSc, Sam Schulman, MD, PhD

August 2019

- Prospective Clinical Trial of DOAC cessation
- 23 centers, US/Canada/Europe
- n= 3007, mean age 72yo,
- procedures: 1000 ↑ bleeding risk, 2000 ↓ risk

PAUSE: elective surgery, nonvalvular afib

- Interruption and resumption strategy: hold NOACS for 1-4 days
- No bridging

Figure. Perioperative Direct Oral Anticoagulant (DOAC) Management Protocol

DOAC	Surgical Procedure-Associated Bleeding Risk	Preoperative DOAC Interruption Schedule						Postoperative DOAC Resumption Schedule			
		Day -5	Day -4	Day -3	Day -2	Day -1		Day +1	Day +2	Day +3	Day +4
Apixaban	High	→					Day of Surgical Procedure = (No DOAC)		→		
	Low	→							→		
Dabigatran esoxilase (CrCl ≥ 50 mL/min)	High	→							→		
	Low	→							→		
Dabigatran esoxilase (CrCl < 50 mL/min) ²	High	→							→		
	Low	→							→		
Rivaroxaban	High	→							→		
	Low	→							→		

PAUSE: 30 day outcomes

	Bleeding	CVA/MI
Apixiban	1.4%	0.2%
Rivaroxiban	1.9%	0.6%
Dabigitran	0.5%	0.4%

*Bleeding risks almost doubled with high risk procedures

PAUSE Study: non-valvular afib

Generally safe to stop NOAC for elective procedures, especially lower risk surgeries.

Perioperative
cardiac risk
assessment
(prevent MACE)



Perioperative cardiac risk assessment


78yo woman with CAD, TIA and OA right hip.

Perioperative evaluation for total hip arthroplasty in 2 weeks.

VSS, exam consistent with OA.

What is the patient's
perioperative cardiac event risk?

- a. <1%
- b. 1-5%
- c. 5-10%
- d. >10%



Perioperative cardiac risk assessment


78yo woman with CAD, TIA and OA right hip.

Perioperative evaluation for total hip arthroplasty in 2 weeks.

VSS, exam consistent with OA.

What is the patient's
perioperative cardiac event risk?

- a. <1%
- b. 1-5%
- c. **5-10%**
- d. >10%



3 most common cardiac risk stratification indices

RCRI

Developed by Goldman 1977
Updated by Lee 1999, then
with more data Duceppe 2017

Most studied!

NSQIP

Developed in 2013 with
1.4M patients by Bilimoria,
now updated: 4.3M pts

Gupta/MICA

Derived from NSQIP
database by Gupta in 2011:
with 200K patients

Revised Cardiac Risk Index

RCRI doesn't discriminate well between outcomes in high vs low risk surgical risk

- Sens 65%
- Spec 76%

Revised Cardiac Risk Index

Patient has...	Points
CAD	1
CHF	1
CVA	1
DM on Insulin	1
Has CKD (Cr >2)	1
High-risk surgery	1

RCRI score	MI, cardiac arrest, death within 30days	95% CI
0	3.9%	2.8%-5.4%
1	6%	4.9%-7.4%
2	10%	8.1%-12.6%
≥3	15%	11.1%-20.0%

Our patient
RCRI = 2

10% MACE event rate
at 30 days

For additional risk stratification, order...

- a. EKG
- b. NT Pro-BNP
- c. Echocardiogram
- d. Exercise Stress Test
- e. CT Coronary Angiogram

Our patient
RCRI = 2 10% MACE event rate
at 30 days

For additional risk stratification, order...

- a. EKG
- b. **NT Pro-BNP**
- c. Echocardiogram
- d. Exercise Stress Test
- e. CT Coronary Angiogram

The Prognostic Value of Pre-Operative and Post-Operative B-Type Natriuretic Peptides in Patients Undergoing Noncardiac Surgery

B-Type Natriuretic Peptide and N-Terminal Fragment of Pro-B-Type Natriuretic Peptide: A Systematic Review and Individual Patient Data Meta-Analysis

JACC 2014 Meta-analysis

- 2179 patients, 18 studies
- 30d outcomes
 - Cardiac events 10.8% (Troponin > 0.04)
 - Death 3% died

RCRI ≥ 1

NT-proBNP \geq

300 = 22% MACE

death or nonfatal MI at 30 days
aOR 3.4 (2.6-4.5)

NT-proBNP \geq

300 = 22% MACE

death or nonfatal MI at 30 days

If < 300 (or BNP < 92) = 4.7% risk

Canadian Cardiovascular Society 2017

Order NT-proBNP or BNP if

- $\text{RCRI} \geq 1$
- Patient $> 65\text{yo}$
- 18-64yo with significant CV dx

Canadian Cardiovascular Society 2017

NT-proBNP \geq

300

Then, recommend:

- Troponin daily for 48-72hrs
- EKG in PACU
- Consider ERAS/care team management

Blood Pressure Medications



Blood Pressure Medications

74yo woman with HTN, for evaluation of semi-elective leiomyoma resection with bleeding.

Meds: HCTZ, lisinopril, amlodipine.

You recommend...

- a. Start metoprolol morning of surgery
- b. Hold lisinopril morning of surgery
- c. Hold amlodipine morning of surgery
- d. Give HCTZ morning of surgery.

Blood Pressure Medications

74yo woman with HTN, for evaluation of semi-elective leiomyoma resection with bleeding.

Meds: HCTZ, lisinopril, amlodipine.

You recommend...

- a. Start metoprolol morning of surgery
- b. Hold lisinopril morning of surgery**
- c. Hold amlodipine morning of surgery
- d. Give HCTZ morning of surgery.

A Systematic Review of Outcomes Associated With Withholding or Continuing Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers Before Noncardiac Surgery

Caryl Hollmann, MBChB, DA(SA), Nicole L. Fernandes, MBChB, DA(SA), and Bruce M. Bickard, MBChB, FCA, PhD

Sept 2018: Systematic Review

- 9 studies: 5 RCT, 4 cohort, n= 6022 patients
- Continued (n=1816) vs stopped ACEI/ARB (n=4206)

Hold ACEI/ARBs to prevent hypotension

Stop ACE/ARB: Mortality unchanged OR 0.97 (0.6 - 1.52)
 MACE unchanged OR 1.1 (0.8 -1.52)
 Less hypotension OR 0.6 (0.5 – 0.85)


Recommendation

- Generally hold ACE on day of surgery, but individualize
- Hypotension risk worst on POD1 (may restart afterwards)

Don't initiate β -blocker (POISE and Bouri)

- increases stroke (1.0% vs 0.5%)
- Increases all cause mortality (3.1% vs 2.3%)
- decreases MI slightly (4.2% vs 5.7%)

Bouri 2014, systematic review (secure trials only shown)



If taking a β -blockers, continue, don't withdraw

- Retrospective cohort @ SFVA
- 1996-2008, n=12,105

All cause 30-day mortality

continuation: aOR 0.74 (95% CI, 0.51-1.05)


withdrawal: aOR 3.57 (95% CI, 2.31-5.52)

1 year mortality

continuation: aOR 0.82 (95% CI, 0.67 to 1.0)

withdrawal: aOR 1.96 (95% CI, 1.49 to 2.58)

PCI and Cardiac Stents



PCI and Cardiac Stents

68yo man with CAD s/p DES 6 months ago presents for perioperative evaluation of elective rotator cuff repair next week. Meds: dual antiplatelet therapy (ASA and Plavix) to prevent in-stent rethrombosis. You recommend:

- a. Proceed with surgery
- b. Delay surgery for 3 months
- c. Delay surgery for 6 months

PCI and Cardiac Stents

68yo man with CAD s/p DES 6 months ago presents for perioperative evaluation of elective rotator cuff repair next week. Meds: dual antiplatelet therapy (ASA and Plavix) to prevent in-stent rethrombosis. You recommend:

- a. **Proceed with surgery**
- b. Delay surgery for 3 months
- c. Delay surgery for 6 months

Waiting after cardiac arterial intervention

New shorter duration from ACC/AHA


TABLE 1

Minimum duration for surgical delay after percutaneous coronary intervention

Type of coronary intervention	Delay for nonurgent surgery
Angioplasty without stenting	14 days ²
Bare-metal stent	30 days ¹⁶
Drug-eluting stent	Optimal: 6 months ¹⁶ 3–6 months if benefits of surgery outweigh risks of stent thrombosis ¹⁶

From references 2 and 16.

2016 ACC/AHA DAPT recs: PCI and stable ischemic heart disease (SIDH)



Based on:

11 new studies DES + shorter duration DES

1 large RCT patients with MI, one year after ASA or DAPT.

Bottom line

- Wait for at least 6 months for DES if you can – don't want to thrombose the stent
- If you can't wait, ortho can operate on antiplatelet therapy (they don't like it, but they usually can!)
- Neurosurgery or major bleeding may require reversal (with platelet transfusion or ddAVP)

summary

Summary: for elective noncardiac surgeries

1. Generally safe to stop DOACs 1-3 days before surgery
2. If RCRI ≥ 1 , get NT-pro-BNP or BNP
3. If NT-proBNP ≥ 300 : PACU EKG & troponins x 48-72hrs
4. Hold ACE/ARB day of surgery and POD1
5. Don't stop or newly start beta-blockers before surgery
6. Don't have to wait as long for DAPT for PCI/stents

Thank you!

